New chemotherapy approaches in colorectal cancer

Axel F Grothey, Hans Joachim Schmoll

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Colorectal cancer is one of the leading causes of cancer deaths in the Western world, with approximately 50% of all patients dying from metastatic disease. Until recently, therapeutic options for advanced colorectal cancer were mainly confined to chemotherapy with 5-fluorouracil in various schedules, with or without biochemical modulation with leucovorin. The development of new cytotoxic drugs with substantial activity in this tumor during the past 2 years has dramatically changed treatment strategies and therapeutic goals in metastatic colorectal cancer and has introduced neoadjuvent chemotherapy followed by secondary surgery with the intent of long-term survival. Among these new drugs, oral fluoropyrimidines (tegafur/uracil and capecitabine), irinotecan, and oxaliplatin have already established themselves as part of various treatment approaches. Other novel therapeutics including agents designed to act on molecular targets already show promising activity and will become part of combination protocols with current standard chemotherapy.

Original languageEnglish (US)
Pages (from-to)275-286
Number of pages12
JournalCurrent Opinion in Oncology
Volume13
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Drug Therapy
irinotecan
oxaliplatin
Tegafur
Therapeutics
Western World
Uracil
Leucovorin
Fluorouracil
Pharmaceutical Preparations
Cause of Death
Neoplasms
Appointments and Schedules
Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

New chemotherapy approaches in colorectal cancer. / Grothey, Axel F; Schmoll, Hans Joachim.

In: Current Opinion in Oncology, Vol. 13, No. 4, 2001, p. 275-286.

Research output: Contribution to journalArticle

Grothey, Axel F ; Schmoll, Hans Joachim. / New chemotherapy approaches in colorectal cancer. In: Current Opinion in Oncology. 2001 ; Vol. 13, No. 4. pp. 275-286.
@article{e6694d3fc33c48279c12d4cbc9842b3b,
title = "New chemotherapy approaches in colorectal cancer",
abstract = "Colorectal cancer is one of the leading causes of cancer deaths in the Western world, with approximately 50{\%} of all patients dying from metastatic disease. Until recently, therapeutic options for advanced colorectal cancer were mainly confined to chemotherapy with 5-fluorouracil in various schedules, with or without biochemical modulation with leucovorin. The development of new cytotoxic drugs with substantial activity in this tumor during the past 2 years has dramatically changed treatment strategies and therapeutic goals in metastatic colorectal cancer and has introduced neoadjuvent chemotherapy followed by secondary surgery with the intent of long-term survival. Among these new drugs, oral fluoropyrimidines (tegafur/uracil and capecitabine), irinotecan, and oxaliplatin have already established themselves as part of various treatment approaches. Other novel therapeutics including agents designed to act on molecular targets already show promising activity and will become part of combination protocols with current standard chemotherapy.",
author = "Grothey, {Axel F} and Schmoll, {Hans Joachim}",
year = "2001",
doi = "10.1097/00001622-200107000-00011",
language = "English (US)",
volume = "13",
pages = "275--286",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - New chemotherapy approaches in colorectal cancer

AU - Grothey, Axel F

AU - Schmoll, Hans Joachim

PY - 2001

Y1 - 2001

N2 - Colorectal cancer is one of the leading causes of cancer deaths in the Western world, with approximately 50% of all patients dying from metastatic disease. Until recently, therapeutic options for advanced colorectal cancer were mainly confined to chemotherapy with 5-fluorouracil in various schedules, with or without biochemical modulation with leucovorin. The development of new cytotoxic drugs with substantial activity in this tumor during the past 2 years has dramatically changed treatment strategies and therapeutic goals in metastatic colorectal cancer and has introduced neoadjuvent chemotherapy followed by secondary surgery with the intent of long-term survival. Among these new drugs, oral fluoropyrimidines (tegafur/uracil and capecitabine), irinotecan, and oxaliplatin have already established themselves as part of various treatment approaches. Other novel therapeutics including agents designed to act on molecular targets already show promising activity and will become part of combination protocols with current standard chemotherapy.

AB - Colorectal cancer is one of the leading causes of cancer deaths in the Western world, with approximately 50% of all patients dying from metastatic disease. Until recently, therapeutic options for advanced colorectal cancer were mainly confined to chemotherapy with 5-fluorouracil in various schedules, with or without biochemical modulation with leucovorin. The development of new cytotoxic drugs with substantial activity in this tumor during the past 2 years has dramatically changed treatment strategies and therapeutic goals in metastatic colorectal cancer and has introduced neoadjuvent chemotherapy followed by secondary surgery with the intent of long-term survival. Among these new drugs, oral fluoropyrimidines (tegafur/uracil and capecitabine), irinotecan, and oxaliplatin have already established themselves as part of various treatment approaches. Other novel therapeutics including agents designed to act on molecular targets already show promising activity and will become part of combination protocols with current standard chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0034955033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034955033&partnerID=8YFLogxK

U2 - 10.1097/00001622-200107000-00011

DO - 10.1097/00001622-200107000-00011

M3 - Article

VL - 13

SP - 275

EP - 286

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -